91 related articles for article (PubMed ID: 8646484)
21. Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation.
Rosenfeld CS; Gremba C; Shadduck RK; Zeigler ZR; Nemunaitis J
Exp Hematol; 1994 Mar; 22(3):290-4. PubMed ID: 7509292
[TBL] [Abstract][Full Text] [Related]
22. Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases.
Alessandrino P; Bernasconi P; Caldera D; Colombo A; Bonfichi M; Malcovati L; Klersy C; Martinelli G; Maiocchi M; Pagnucco G; Varettoni M; Perotti C; Bernasconi C
Bone Marrow Transplant; 1999 Mar; 23(6):533-7. PubMed ID: 10217182
[TBL] [Abstract][Full Text] [Related]
23. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.
Filip S; Bláha M; Odrázka K; Mericka P; Vávrová J
J Hematother Stem Cell Res; 2000 Feb; 9(1):31-8. PubMed ID: 10738969
[TBL] [Abstract][Full Text] [Related]
24. Peripheral blood progenitor cell mobilisation alters myeloid, but not erythroid, progenitor cell self-renewal kinetics.
Marley SB; Lewis JL; Zheng B; Davidson RJ; Davis JG; McDonald C; Alenzi FQ; Goldman JM; Gordon MY
Bone Marrow Transplant; 2001 Feb; 27(3):241-8. PubMed ID: 11277171
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies.
Sheridan WP; Begley CG; To LB; Grigg A; Szer J; Maher D; Green MD; Rowlings PA; McGrath KM; Cebon J
Bone Marrow Transplant; 1994 Jul; 14(1):105-11. PubMed ID: 7524904
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
[TBL] [Abstract][Full Text] [Related]
27. Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy.
Zimmerman TM; Mick R; Myers S; Bender JG; Lee WJ; Williams SF
Bone Marrow Transplant; 1995 Jun; 15(6):923-7. PubMed ID: 7581092
[TBL] [Abstract][Full Text] [Related]
28. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC).
Benet I; Prosper BF; Marugan I; Lluch A; Arbona C; Castillo I; Solano C; Garcia-Conde J
Bone Marrow Transplant; 1999 Jun; 23(11):1101-7. PubMed ID: 10382948
[TBL] [Abstract][Full Text] [Related]
29. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
30. Post-thaw viability of cryopreserved hematopoietic progenitor cell grafts: does it matter?
Vrhovac R; Perić Z; Jurenec S; Kardum-Skelin I; Jelić-Puskarić B; Jaksić B
Coll Antropol; 2010 Mar; 34(1):163-9. PubMed ID: 20432746
[TBL] [Abstract][Full Text] [Related]
31. Long-term cryopreservation of bone marrow for autologous transplantation.
Attarian H; Feng Z; Buckner CD; MacLeod B; Rowley SD
Bone Marrow Transplant; 1996 Mar; 17(3):425-30. PubMed ID: 8704699
[TBL] [Abstract][Full Text] [Related]
32. Determining factors for the outcome of peripheral blood progenitor cells harvests.
Keung YK; Cobos E; Dunn D; Park M; Dixon S; Wu K; Park CH
J Clin Apher; 1996; 11(1):23-6. PubMed ID: 8722718
[TBL] [Abstract][Full Text] [Related]
33. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
[TBL] [Abstract][Full Text] [Related]
34. The effect of short G-CSF administration on the numbers and clonogenic efficiency of hematopoietic progenitor cells in bone marrow and peripheral blood of normal donors.
Zaucha JM; Knopińska-Posłuszny W; Bieniaszewska M; Myśliwski A; Hellmann A
Ann Transplant; 2000; 5(4):20-6. PubMed ID: 11499355
[TBL] [Abstract][Full Text] [Related]
35. Mobilization of peripheral blood progenitor cells by disease-specific chemotherapy in patients with soft tissue sarcoma.
Schwella N; Rick O; Meyer O; Löffel J; Schleicher J; Serke S; Huhn D; Riess H
Bone Marrow Transplant; 1998 May; 21(9):863-8. PubMed ID: 9613776
[TBL] [Abstract][Full Text] [Related]
36. Controlled-rate versus uncontrolled-rate cryopreservation of peripheral blood progenitor cells: a prospective multicenter study. Group for Cryobiology and Biology of Bone Marrow Transplantation (CBTMO), Spain.
Perez-Oteyza J; Bornstein R; Corral M; Hermosa V; Alegre A; Torrabadella M; Ramos P; Garcia J; Odriozola J; Navarro JL
Haematologica; 1998 Nov; 83(11):1001-5. PubMed ID: 9864921
[TBL] [Abstract][Full Text] [Related]
37. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant.
Bolwell BJ; Goormastic M; Yanssens T; Dannley R; Baucco P; Fishleder A
Bone Marrow Transplant; 1994 Dec; 14(6):913-8. PubMed ID: 7536072
[TBL] [Abstract][Full Text] [Related]
38. Thawed autologous peripheral blood stem cells require modified quantification methods for hematopoietic progenitor cell evaluation.
Decot V; Alla F; Latger-Cannard V; Visanica S; Witz B; Stoltz JF; Bensoussan D
Biomed Mater Eng; 2012; 22(1-3):57-67. PubMed ID: 22766703
[TBL] [Abstract][Full Text] [Related]
39. Cryopreservation of hematopoietic progenitor cells from apheresis at high cell concentrations does not impair the hematopoietic recovery after transplantation.
Martin-Henao GA; Torrico C; Azqueta C; Amill B; Querol S; Garcia J
Transfusion; 2005 Dec; 45(12):1917-24. PubMed ID: 16371044
[TBL] [Abstract][Full Text] [Related]
40. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
